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Short titleSC tape stripping in AD children with light and dark skin types 
What’s already known about this topic?  
AD affects children of all skin types, but most research is focused on Caucasians with light 
skin types. Studies investigating biomarkers in AD patients with dark skin types are lacking. 
Tape stripping can be used for analysis of skin barrier and immune response biomarkers in 
AD skin.  
This is the peer reviewed version of the following article: Hulshof, L. et al., 'Stratum corneum 
analysis provide a minimal invasive tool to study immune response and skin barrier in atopic 
dermatitis children', British Journal of Dermatology (2018), which has been published in final 
form at https://doi.org/10.1111/bjd.16994. This article may be used for non-commercial 
purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
What does this study add?  
SC tape stripping is suitable to study a broad panel of biomarkers in AD children. We show 
differences in skin barrier and immune response biomarkers between lesional, non-lesional 
and control skin. Immune response biomarkers are similar in light and dark skin types. 
However, NMF levels differ between skin type II and VI, hinting towards a possible different 
pathogenesis in AD between light and dark skin types.  
 
Summary 
Background Atopic dermatitis (AD) affects children of all skin types, most research is focused on 
Caucasians with light skin types. Studies investigating biomarkers in AD patients with dark skin types 
are lacking.  
Objectives To explore skin barrier and immune response biomarkers in stratum corneum (SC) tape 
strips from AD children with different skin types. 
Methods Tape strips were collected from lesional and non-lesional forearm skin of 53 AD children 
and 50 control children. We analysed 28 immunomodulatory mediators, as well as natural 
moisturizing factors (NMF) and corneocyte morphology with atomic force microscopy.  
Results IL1β, IL18, CXCL8, CCL22, CCL17, CXCL10 and CCL2 were significantly (p<0.05) higher in 
lesional AD skin versus non-lesional AD skin, while IL-1 α showed the opposite trend. CXCL8, CCL2 
and CCL17 showed association with oSCORAD. NMF levels showed a gradual decrease from healthy 
skin to non-lesional and lesional AD skin. This gradual decreasing pattern was observed in skin type II 
but not in skin type VI. Skin type VI showed higher NMF levels in both non-lesional and lesional AD 
skin compared to skin type II. Corneocyte morphology was significantly different in lesional AD skin 
versus non-lesional AD and healthy skin. 
Conclusions Minimally invasive tape stripping is suitable for determination of many inflammatory 
mediators and skin barrier biomarkers in AD children. This explorative study shows differences 
between AD children with skin type II and skin type VI in NMF levels, suggesting that some aspects of 
pathophysiological mechanisms may differ in AD children with light versus dark skin types.  
 
Keywords atopic dermatitis, stratum corneum analysis, biomarkers, children, natural moisturizing 
factor, skin barrier, skin type differences 
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Abbreviations 
AD   Atopic dermatitis 
AFM  Atomic force microscopy 
AMC   Academic Medical Centre,  Amsterdam, the Netherlands 
BH  Benjamini-Hochberg 
CCL  CC chemokine ligand (-2,-3,-4,-11,-13,-17,-18,-22,-26) 
CTRL  Healthy skin of controls 
CXCL  CXC chemokine ligand (-8,-10) 
DTI  Dermal Texture Index 
FDR  False discovery rate 
FLG  Filaggrin 
GM-CSF Granulocyte-macrophage colony-stimulating factor  
HIS  Histidine 
IL  Interleukin (-1,-1α,-1β,-2,-4,-5,-6,-7,,-10,-12p40,-12p70,-13,-15,-16,-17A,-18) 
INF  Interferon (-γ) 
IQR   Interquartile Range (Q1-Q3) 
L  Lesional AD skin 
MWU  Mann Whitney U test 
NL  Non-lesional AD skin 
NMF  Natural Moisturizing factor 
oSCORAD Objective SCORAD score 
PCA  Pyrolidone-5carboxylic acid  
SCORAD Score Scoring atopic dermatitis score, clinical tool for scoring AD severity 
SC  Stratum corneum 
SD  Standard deviation 
SEM  Scanning electron microscopy 
TEWL  Trans-epidermal water loss 
Th2  T helper cell type 2 
TNF  Tumor necrosis factor (-α) 
UCA  Urocanic acid 
VP  Villus-like projections 
W-test  Wilcoxon test 
 
Introduction   
Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 10-20% of children 
(1). AD affects children of all skin types and seems more prevalent in Asian and children 
with dark skin types (2, 3). However, most research is focused on Caucasians with light skin 
types and studies investigating biomarkers in AD patients with dark skin types is lacking. 
Data on physiological skin properties in different skin types is conflicting. Darker skin types 
seem more resistant to irritants than lighter skin types (4), but trans-epidermal water loss 
(TEWL) seems  greater in dark skin types compared to lighter skin types (5). Furthermore, 
the stratum corneum (SC) of dark skin types shows higher lipid content and seems more 
compact due to greater intercellular cohesion. (6, 7). Nevertheless, the SC thickness is 
demonstrated to be similar for all different skin types (8). The SC and filaggrin (FLG) have a 
crucial role in forming the epidermal barrier (9). FLG degradation products, such as histidine 
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(HIS), pyrolidone-5carboxylic acid (PCA) and urocanic acid (UCA), are the main source of 
natural moisturizing factors (NMF) and are responsible for mechanical properties, skin 
hydration and inflammatory response in skin (10).  
In AD patients, abnormalities in corneocyte morphology such as prominent villus-like 
projections (VP) have been observed using high-resolution atomic force microscopy (AFM) 
(11, 12). Although the nature of these VP is not well understood, VP can be used to 
measure skin barrier function (11). The number of VP per investigated corneocyte area is 
expressed as the Dermal Texture Index score (DTI). In AD children, a strong negative 
association was found between NMF levels and corneocyte morphology abnormalities 
measured by DTI (13). Moreover, these DTI values in AD children with FLG mutations might 
explain phenotypic differences in AD (13).  
Serum inflammatory profiles are investigated to gain more insight in immune pathways and 
future personalised therapeutic options. Cytokines (IL4, CXCL8, IL13) and chemokines 
(CCL2, CCL17, CCL18, CCL22) are correlated with AD severity in adults (14-16).  However, 
obtaining blood samples and skin biopsies is difficult in children, therefore detailed data of 
skin samples are lacking. A minimally invasive method to detect biomarkers would provide 
an essential tool in dissection of childhood AD into disease endotypes, and predicting or 
monitoring flares and therapy efficacy in childhood AD.     
Our aim was to use the minimally invasive method of SC tape stripping to study a large array 
of SC biomarkers including immunomodulatory mediators, NMF and DTI in AD children 
compared to children with healthy skin. We assessed differences in these biomarkers in light 
skin types compared to dark skin types, and in children with and without FLG mutations.  
 
 
Patients and methods  
AD patients and healthy controls 
Children (0-12 years) diagnosed with AD according to the UK working party criteria (17-19) 
were recruited (2015-2016) from the paediatric and dermatology outpatient clinic in a tertiary 
referral centre, Academic Medical Center (AMC). Children treated with systemic 
corticosteroids, antibiotics, antimycotics or extensive UV exposure 4 weeks prior to tape 
stripping were excluded, and children were instructed not to use antihistamines (72 hours) 
and emollients, soap and perfumes on the selected forearm (48 hours). For AD children the 
forearm skin should not have been treated with topical corticosteroids (1 week). AD severity 
was assessed using objective scoring atopic dermatitis score (oSCORAD) (20, 21).  
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Control children (no medical history of inflammatory skin disorders or AD, and no first degree 
relatives with AD) with healthy skin were recruited from the AMC surgery outpatient clinic.  
Skin types were categorised according to Fitzpatrick skin phototypes, ranging from I to VI 
(22). Analyses were limited to skin types II and VI due to low sample sizes of remaining skin 
types.  
 
SC tape-stripping  
The SC was collected, as previously described (23) by tape stripping a visibly non-lesional 
skin site of the forearm, and in some AD children also from a lesional site of the forearm. 
Circular adhesive tapes (D-squame® discs, 22 mm diameter, 3.8 cm2, Monaderm, Monaco, 
France) were placed to volar forearm and pressed for ten seconds with a pressure of 225 
g/cm2 of D-Squame Pressure Instrument D500 (CuDerm Corporation, Dallas, Texas). 
Sequentially, 6 consecutive tapes from the same skin site were collected. The 3rd and 4th 
tape strip for determining corneocyte morphology and NMF were stored at -20°C, all other 
tape strips were stored at -80°C until analysis.  
 
FLG genotyping 
We analysed the four most prevalent FLG mutations (R501X, 2282del4, R2477X,S3247X) 
from DNA extracted from a buccal swab as previous described (24, 25).  
 
Immunomodulatory mediators 
Levels of 28 immunomodulatory mediators (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12p40, IL-12p70, IL-13,  IL-15, IL-16, IL-17A, IL-18, IFN-γ, TNF-α, GM-CSF, CXCL8, 
CXCL10, CCL2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL22 and CCL26) were 
determined in the 5th and 6th tape strip, representing the SC middle part, using the MESO 
QuickPlex SQ 120 assay (MSD, Rockville, Md., USA) on samples extracted by 
ultrasonification (15 min) with 0.5 ml of phosphate-buffered saline containing 0.05% Tween 
20 and stored at -80 °C according to manufactory protocol. Samples under the limit of 
detection were substituted for by a value of half the level of the detection limit. Levels were 
corrected by total protein content, as determined using Pierce Micro BCA protein assay kit 
(Thermo Fischer Scientific, Rockford, IL, USA,). 
NMF determination 
NMF components PCA, His and UCA (cis- and trans isomer) were extracted with 500 µL of 
25% (w/w) ammonia solution, reconstituted in 500 µL water after evaporating ammonia and 
analysed by HPLC-UV as described previously (23,26). NMF concentrations were also 
corrected for total protein content and expressed as mmol/g protein. 
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Corneocyte morphology (DTI)  
In a randomly chosen subgroup (16 controls and 21 AD children) with skin type II or VI 
corneocytes morphology was analysed with AFM as described previously (27, 28). Besides 
analysis of non-lesional skin, in 13 AD children DTI was also determined in lesional skin. 
AFM was used on the 3rd tape strip with a Nanoscope III controller and software version 
5.30sr3 (Digital Instruments, Santa Barbara, CA, USA) (27). For nano-texture analysis, 
subcellular scan areas of (20 µm)2 were recorded (13). A recently developed software 
method can quantitatively determine the VP surface nano-texture on corneocytes. 
Topographical data of cell surfaces of the tape strips was analysed using Anostic™-method 
applying custom built, proprietary algorithms (13) enabling assessment of the number of 
nano-size protrusion. The number of these protrusions per (20 µm)2unit area has been 
expressed as the DTI score (13).  
 
Statistical analysis 
Data analysis was done by SPSS version 24 (IBM SPSS Statistics for Windows, Armonk, 
New York, USA) and GraphPad prism® version 7.0 (GraphPad Software, La Jolla, 
California, USA). Baseline characteristics were analyzed by Student’s t-test (for normally 
distributed continuous data), Mann–Whitney U-test (for nonparametric continuous data), chi-
square test (for dichotomous data). Distribution of data was tested by Shapiro-Wilk normality 
test. Mann Whitney U test (MWU-test) was used for unpaired comparison between groups 
(healthy versus lesional skin) and Wilcoxon Signed Rank test (W-test) for comparison within 
the AD group (non lesional versus lesional skin). A two-tailed nonparametric Spearman 
correlation analysis was used to determine the overall associations between biomarkers and 
oSCORAD. Multiple linear regression analysis was performed with skin severity as 
dependent and biomarkers, skin type and FLG mutations as independent variables using 
stepwise backward selection method. Because of skewed distribution cytokine levels were 
log-transformed before linear regression analysis. Correction for multiple testing, using the 
Benjamini-Hochberg (BH) method was conducted for all the resulting p-values, the corrected 
p-values <0.05 were considered significant.  
 
Results  
Patient characteristics 
Demographic characteristics are shown in Table 1. Control children were slightly older. AD severity 
was mild to moderate with a mean oSCORAD of 17.6 (± SD 9.7). Within the AD group, FLG mutations 
were less prevalent in darker skin types, as only 1 child with skin type VI (1/14; 7%) had a FLG 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
mutation, while 64% (9/14) of skin type II AD children had a FLG mutation. Most children were 
investigated in summer season (76% controls versus 49% AD children).  
 
Distinct inflammatory immune responses can be detected in SC of AD children  
From 28 measured immunomodulatory mediators 13 could quantitatively be determined in 
SC samples. In 9 of the 13 immunomodulatory mediators significant differences were found 
between healthy, non-lesional and/or lesional skin. IL1α was significantly lower (p<0.05) in 
non-lesional AD skin compared to healthy skin of controls, which was even more 
pronounced (p<0.01) when compared to lesional AD skin (Figure 1a). A similar incremental 
pattern from healthy to non-lesional and lesional skin, but in opposite direction could be seen 
for IL1β and IL18 (Figure 1b-c).  
CXCL8 and CCL2, CCL22 and CCL17 were significantly higher in lesional AD skin 
compared to healthy and non-lesional AD skin (Figure 2a,b,c,e).  An opposite pattern was 
found for CCL4 which was  significantly reduced in non-lesional and/or lesional AD skin as 
compared to healthy skin (Figure 2d).  Significant differences between healthy and non-
lesional skin, and between non-lesional and lesional skin were found for chemokine CXCL10 
(Figure 2f). No significant difference in levels of IL4, IL13, CCL13 and CCL11 was found 
between healthy skin, lesional and non-lesional AD skin (data not shown).   
Although for a few cytokines the level of significance for the comparison between healthy, 
non-lesional and/or lesional skin differ between skin type II and skin type VI, the overall 
pattern is similar for these two skin types (Supplementary Figure S1).   
 
Inflammatory immune responses correlate with AD severity  
 Associations between oSCORAD and immunomodulatory mediators are shown in Table 2. 
CXCL8 is significantly correlated with oSCORAD in both lesional as well as non-lesional AD 
skin. CCL17 shows a significant correlation with oSCORAD in non-lesional AD skin and a 
trend towards a significant correlation in lesional AD skin (p=0.053). In lesional AD skin 
CCL2 is significantly correlated with oSCORAD.  The relationship between oSCORAD and 
biomarkers has further been investigated by multivariate linear regression analysis including 
a set of biomarkers which were significantly correlated with oSCORAD in non-lesional and/or 
lesional AD skin (CXCL8, CCL2, and CCL17). Next to these three biomarkers, we included 
as independent variables FLG mutations and skin types. In non-lesional AD skin, the model 
with CXCL8, CCL2, CCL17, skin type and FLG mutation shows a significant effect on 
oSCORAD (r 0.50, p<0.05). In lesional AD skin, only CXCL8 and skin type were significant 
predictors of oSCORAD (r 0.52, p<0.05). In general, prediction of oSCORAD did not 
substantially improve as compared to single biomarkers (Table 2).  
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NMF levels show a trend of gradual decrease from healthy skin to non-lesional and 
lesional AD skin  
NMF levels gradually decreased from healthy skin (median 3.1 (IQR 2.0-4.1)) to non-lesional 
AD skin (median 2.8  (IQR 1.8-3.6)), with a further decrease in lesional AD skin (median 1.9 
mmol per gram protein (IQR Q1-Q3 1.0-3.6)), but no significant differences were found  
(Figure 3a). Although NMF levels in FLG mutation carriers seemed to be lower than in wild-
type subjects, there was no significant difference between the groups (Figure 3b).  
 
NMF levels show different profiles between light and dark skin types  
NMF levels were significantly lower in skin type II compared to skin type VI in both lesional 
and non-lesional AD skin (p<0.05; Figure 4b,c). In healthy skin, NMF levels were not 
different between skin types (Figure 4a).  
When comparing NMF between healthy, non-lesional and lesional skin within skin types, 
NMF levels within skin type II seem to decrease sequentially in healthy skin to non-lesional 
and to lesional AD skin (Figure 5a), reaching significance when comparing healthy skin to 
lesional AD skin (p <0.01). No significant differences could be seen when analyzing only 
FLG wild-type subjects, although a similar decreasing pattern was seen (Fig 5b). In contrast, 
in skin type VI, NMF levels were not significantly different between healthy skin and either 
non-lesional or lesional AD skin (Figure 5c) 
 
AD skin has altered corneocyte texture in both lesional and non-lesional skin  
Figure 6 shows representative AFM images of the surfaces of corneocytes sampled from 
lesional and non-lesional skin of AD children and of  healthy skin. DTI values were 
significantly higher in lesional AD skin compared to both non-lesional AD skin (p <0.05) and 
healthy skin (p<0.01); Figure 7). DTI values within skin type II showed a sequential increase 
from healthy skin to non-lesional and lesional AD skin, with a significant difference between 
healthy skin and lesional AD skin (Figure 8a). There was no significant difference between 
healthy, non-lesional and lesional AD skin in skin type VI (Figure 8b). 
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DISCUSSION  
The SC is largely responsible for skin barrier function and furthermore harbours a large 
variety of inflammatory mediators involved in immune responses. Skin biomarkers research 
in AD children is hampered by invasiveness of sampling techniques such as skin biopsy or 
blood collection. To our best knowledge, the present study shows for the first time that the 
minimally invasive method of SC tape stripping is suitable for determination of a large array 
of skin barrier and immune response biomarkers in AD children, investigating differences 
between AD skin and healthy control skin. Furthermore, it is the first time that biomarkers 
differences are investigated between light and dark skin types.  
 
Several immunomodulatory mediators showed significant differences between healthy and 
atopic skin. IL1α, an IL-1 cytokine constitutively produced by keratinocytes and present in 
SC in large amounts showed significant differences between healthy and non-lesional AD 
skin, and even more pronounced differences between healthy and lesional AD skin. As IL1α 
is stored within the corneocyte, skin barrier damage leads to leakage of IL1α into 
extracellular space. A similar effect was seen in irritant contact dermatitis which is 
associated with skin barrier damage (29). IL1β and IL18, two other IL-1 family cytokines, 
also showed significant differences between healthy and lesional AD skin and between non-
lesional and lesional AD skin. IL18 is associated with Staphylococcus aureus colonization, a 
common feature in AD (30). A decrease of IL1α and increase of IL1β and IL18 from healthy 
skin to non-lesional to lesional AD skin is in agreement with data from a previous study in 
interstitial fluid in AD which reveals that SC reflects the same cytokine milieu as viable 
epidermis (31). 
Previously, a meta-analysis of literature data found serum CCL17 as the most promising 
single biomarker of AD severity. Our data showed that  CCL17 in non-lesional  AD skin was 
significantly correlated with oSCORAD, and showed a trend towards correlation in lesional 
AD skin. Next to CCL17, a significant correlation with oSCORAD was found for CXCL8 in 
both lesional and non-lesional AD skin and for CCL2 in lesional AD skin. Interestingly, levels 
of CCL17 and CXCL8 showed a correlation with disease severity in non-lesional skin, 
suggesting that SC samples also provide information on systemic immune response, which 
is in agreement with a recent study reporting that non-lesional markers generally showed 
higher and more significant correlations with SCORAD than lesional markers (32). 
 
One of the aims of the present study was to explore possible differences in immune 
response and skin barrier between different skin types. As the sample size within the skin 
type groups was small, we performed comparison only between the largest subgroups: light 
skin type II and dark skin type VI. There was no clear difference in the levels of 
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immunomodulatory mediator profiles between these two subgroups. However, AD children 
with skin type II showed lower NMF levels in both non-lesional and lesional AD skin as 
compared to skin type VI, although both groups had comparable disease severity. As FLG 
mutations are the main determinant of NMF and they were more prevalent in skin type II, we 
also performed the comparison in only the children without FLG mutations. When excluding 
FLG mutation carriers, the NMF levels in skin type II group still showed a trend towards a 
difference between healthy skin, lesional and non-lesional AD skin, suggesting the effect of 
AD on the NMF levels in the light skin type. Interestingly, within skin type VI, there was no 
significant difference in NMF between healthy skin and either non-lesional or lesional AD 
skin. Consistent with our study where only one carrier of FLG mutations within skin type VI 
has been detected, different studies have reported that the prevalence of FLG mutations in 
African AD patients is very low compared to European Caucasians (33,34). Although rare 
population-specific mutations cannot be excluded, it is not likely that they would have largely 
influenced the results on NMF levels found in the present study. Another skin barrier 
parameter, DTI showed a sequential increase from healthy skin to non-lesional and lesional 
AD skin within skin type II with a significant difference between healthy skin and lesional AD 
skin. However, this pattern of gradual increase was not present in skin type VI and no 
significant differences were seen. In general, data on differences in skin barrier between 
different skin types and ethnicities is scarce. Several studies reported differences in TEWL, 
lipid content, ceramides, intercellular cohesion and skin pH in African American children as 
compared to Caucasians and East Asians. As TEWL, intercellular cohesion and skin pH are 
known to be affected by NMF, (5, 7, 35) it would be interesting to investigate whether higher 
NMF in children of skin type VI found in the present study are correlated to these important 
parameters of the skin barrier function. 
Our study has several limitations; the sample size was relatively small and not powered on 
differences between skin types, accordingly, subgroup analyses in all skin types were not 
possible.  Since there was a significant difference in sampling period, as the majority (76%) 
of healthy controls were seen during summer compared to 49% of AD children. UV exposure 
may have influenced NMF levels and DTI values in controls (36). 
 
In conclusion, collecting SC samples with minimal invasive tape strip method is suitable for 
determination of a large array of immunomodulatory mediators and skin barrier biomarkers 
in AD children. CXCL8, CCL2, and CCL17 are the most promising biomarkers to assess the 
severity of disease. This study shows that immunomodulatory mediator profiles are similar in 
light and dark skin types, but that NMF levels and DTI values differ between AD children with 
skin type II and skin type VI. This may suggest a different role for skin barrier dysfunction in 
the pathogenesis of AD between light and dark skin types.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Ethical statement  
The study was conducted according to principles of the Declaration of Helsinki and was 
approved by the Ethics Committee of the Academic Medical Centre (AMC) and approved by 
the Medical Ethics Review Committee of the AMC Amsterdam (METC 2013_372). Written 
informed consent was obtained from both parents/legal guardians of all children.  
 
Conflict of interest  
B.L., as indicated by the affiliations, is leading the strategic alliance between the University 
Medical Centre Utrecht/Wilhelmina Children’s Hospital and Nutricia Research and is 
employed by Nutricia Research. All other co-authors declare no potential conflict of interest. 
 
Author contributions  
Performed the study; L.H., D.H.,B.D., A.S., M.M. Designed and supervised the study; S.K., 
A.S, M.M, W.A. Participated in data collection, analyses and Interpretation; L.H.; 
D.H.;Q.H.;B.D.; I.J.; B.L.;S.K.;A.S.;M.M.;W.A;C.R.;W.L.;L.C. Drafted the manuscript 
L.H.;D.H.; Q.H; B.D.; S.K.; A.S.; M.M.  
All authors revised and approved the final version of the manuscript. 
 
Funding  
This study was supported by an unrestricted grant from the “Stichting Steun Emma” 
Academic Medical Hospital Amsterdam. 
 
Acknowledgements  
Most of all we like to thank all the participating children and their families. In addition, we 
wish to thank all the assistants of the pediatrician, dermatology and surgical department of 
the out-patient clinics for their dedication for recruiting participants. We thank the 
laboratories of the cooperating institutes and their staff for the technical assistance and 
excellent lab work, especially Florentine Kwa-Calkoen.  
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
References 
 
1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22. 
2. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data 
from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73. 
3. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic Dermatitis in Diverse Racial and Ethnic 
Groups - Variations in Epidemiology, Genetics, Clinical Presentation, and Treatment. Exp Dermatol. 
2018. 
4. Hicks SP, Swindells KJ, Middelkamp-Hup MA, Sifakis MA, Gonzalez E, Gonzalez S. Confocal 
histopathology of irritant contact dermatitis in vivo and the impact of skin color (black vs white). J 
Am Acad Dermatol. 2003;48(5):727-34. 
5. Wesley NO, Maibach HI. Racial (ethnic) differences in skin properties: the objective data. Am 
J Clin Dermatol. 2003;4(12):843-60. 
6. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic 
disease. J Am Acad Dermatol. 2002;46(2 Suppl Understanding):S41-62. 
7. Czerkasij V. Skin of color: a basic outline of unique differences. Nurse Pract. 2013;38(5):34-
40; quiz -1. 
8. La Ruche G, Cesarini JP. [Histology and physiology of black skin]. Ann Dermatol Venereol. 
1992;119(8):567-74. 
9. Sandilands A, Sutherland C, Irvine AD, McLean WH. Filaggrin in the frontline: role in skin 
barrier function and disease. J Cell Sci. 2009;122(Pt 9):1285-94. 
10. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy 
Clin Immunol. 2013;131(2):280-91. 
11. Naoko O, Satoshi H, Fukuyoshi M, Mitsuyoshi H. Changes in villus-like projections of 
corneocytes from the facial skin in normal infants with or without infantile eczema; useful 
parameter to assess barrier function. Skin Res Technol. 2013;19(4):361-7. 
12. Gorzelanny C, Goerge T, Schnaeker EM, Thomas K, Luger TA, Schneider SW. Atomic force 
microscopy as an innovative tool for nanoanalysis of native stratum corneum. Exp Dermatol. 
2006;15(5):387-91. 
13. Riethmuller C, McAleer MA, Koppes SA, Abdayem R, Franz J, Haftek M, et al. Filaggrin 
breakdown products determine corneocyte conformation in patients with atopic dermatitis. J Allergy 
Clin Immunol. 2015;136(6):1573-80 e2. 
14. Morita E, Takahashi H, Niihara H, Dekio I, Sumikawa Y, Murakami Y, et al. Stratum corneum 
TARC level is a new indicator of lesional skin inflammation in atopic dermatitis. Allergy. 
2010;65(9):1166-72. 
15. Amarbayasgalan T, Takahashi H, Dekio I, Morita E. Interleukin-8 content in the stratum 
corneum as an indicator of the severity of inflammation in the lesions of atopic dermatitis. Int Arch 
Allergy Immunol. 2013;160(1):63-74. 
16. Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. 
Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin 
Immunol. 2015;15(5):453-60. 
17. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The U.K. Working 
Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for 
atopic dermatitis. Br J Dermatol. 1994;131(3):383-96. 
18. Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party's Diagnostic Criteria for 
Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J 
Dermatol. 1994;131(3):397-405. 
19. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria 
for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406-16. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
20. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for 
the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 
1997;195(1):10-9. 
21. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on 
interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item 
severity score. Br J Dermatol. 2007;157(4):645-8. 
22. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch 
Dermatol. 1988;124(6):869-71. 
23. Dapic I, Jakasa I, Yau NLH, Kezic S, Kammeyer A. Evaluation of an HPLC Method for the 
Determination of Natural Moisturizing Factors in the Human Stratum Corneum. Anal Lett. 
2013;46(14):2133-44. 
24. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan GM, Clayton TH, Watson RM, et al. 
Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in 
ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39(5):650-4. 
25. Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, Wilson IJ, et al. Filaggrin null mutations 
and childhood atopic eczema: a population-based case-control study. J Allergy Clin Immunol. 
2008;121(4):940-46 e3. 
26. Kezic S, Kammeyer A, Calkoen F, Fluhr JW, Bos JD. Natural moisturizing factor components in 
the stratum corneum as biomarkers of filaggrin genotype: evaluation of minimally invasive methods. 
Br J Dermatol. 2009;161(5):1098-104. 
27. Franz J, Beutel M, Gevers K, Kramer A, Thyssen JP, Kezic S, et al. Nanoscale alterations of 
corneocytes indicate skin disease. Skin Res Technol. 2016;22(2):174-80. 
28. Riethmuller C, Schaffer TE, Kienberger F, Stracke W, Oberleithner H. Vacuolar structures can 
be identified by AFM elasticity mapping. Ultramicroscopy. 2007;107(10-11):895-901. 
29. Koppes SA, Ljubojevic Hadzavdic S, Jakasa I, Franceschi N, Jurakic Toncic R, Marinovic B, et al. 
Stratum corneum profiles of inflammatory mediators in patch test reactions to common contact 
allergens and sodium lauryl sulfate. Br J Dermatol. 2017;176(6):1533-40. 
30. Inoue Y, Aihara M, Kirino M, Harada I, Komori-Yamaguchi J, Yamaguchi Y, et al. Interleukin-
18 is elevated in the horny layer in patients with atopic dermatitis and is associated with 
Staphylococcus aureus colonization. Br J Dermatol. 2011;164(3):560-7. 
31. Szegedi K, Lutter R, Res PC, Bos JD, Luiten RM, Kezic S, et al. Cytokine profiles in interstitial 
fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol. 2015;29(11):2136-44. 
32. Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An Integrated 
Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Invest 
Dermatol. 2017;137(3):603-13. 
33. Margolis DJ, Gupta J, Apter AJ, Ganguly T, Hoffstad O, Papadopoulos M, et al. Filaggrin-2 
variation is associated with more persistent atopic dermatitis in African American subjects. J Allergy 
Clin Immunol. 2014;133(3):784-9. 
34. Margolis DJ, Mitra N, Gochnauer H, Wubbenhorst B, D'Andrea K, Kraya A, et al. Uncommon 
filaggrin variants are associated with persistent atopic dermatitis in African Americans. J Invest 
Dermatol. 2018. 
35. Vachiramon V, Tey HL, Thompson AE, Yosipovitch G. Atopic dermatitis in African American 
children: addressing unmet needs of a common disease. Pediatr Dermatol. 2012;29(4):395-402. 
36. Engebretsen KA, Kezic S, Riethmuller C, Franz J, Jakasa I, Hedengran A, et al. Changes in 
filaggrin degradation products and corneocyte surface texture by season. Br J Dermatol. 2018. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Figure legends  
Figure 1 Levels of IL-1 cytokines (IL-1a, IL-1b and IL-18) in healthy skin of control children (CTRL 
green/●, n=49) and in AD children with non-lesional and lesional skin (NL blue/■, n=53 and L red/▲, 
n=24). The differences in IL-1 cytokines between healthy and AD skin were tested by Mann Whitney 
U test. Wilcoxon Signed Rank test was used to test differences between the unaffected and affected 
AD skin. Statistically significant differences; Benjamini-Hochberg  corrected p-values are  indicated 
with asterisks: * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 2 Cytokine and chemokines levels in healthy skin of control children (CTRL green/●, n=49) 
and AD children with non-lesional or lesional skin (NL blue/■, n=53 and L red/▲, n=24). The 
differences in chemokine levels between healthy and AD skin were tested by Mann Whitney U test. 
Wilcoxon Signed Rank test was used to test differences between non-lesional and lesional AD skin. 
Statistically significant differences; Benjamini-Hochberg  corrected p-values are indicated with 
asterisks: * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure S1 immunomodulatory mediators within skin type II and VI in healthy skin of control children 
(CTRL green/●), non-lesional AD skin (NL blue/■) and lesional AD skin (L red/▲) are shown. The 
differences in chemokine levels between healthy and AD skin were tested by Mann Whitney U test. 
Wilcoxon Signed Rank test was used to test differences between non-lesional and lesional AD skin. 
Statistically significant differences; Benjamini-Hochberg  corrected p-values are indicated with 
asterisks: *p<0.05; **p<0.01. 
 
Figure 3 Differences in the natural moisturizing factor levels (NMF) in stratum corneum (SC) in 
healthy skin of control children and in non-lesional and lesional skin of AD children. The results of 
n=49 healthy skin of control children (CTRL ●), n=53 non-lesional AD skin (NL ■) and n=25 lesional 
AD skin (L ▲) are shown. The red marked symbols represent children with FLG-loss-off-function 
mutation(s);CTRL n=3, NL n=14, L n=6. Data are shown as median with interquartile ranges (IQR Q1-
Q3). A Mann Whitney U test (MWU-test) was used to investigate significant difference between 
healthy skin versus unaffected AD skin, as the Wilcoxon matched-pairs signed rank test (W-test) was 
used to investigate differences between the paired samples of unaffected versus affected AD skin. 
Statistically significant differences; Benjamini-Hochberg  corrected p-values are indicated with 
asterisks: *p<0.05.  
 
Figure 4 Natural moisturizing factor levels (NMF) in stratum corneum (SC) of skin type II and VI in a) 
healthy skin of control children (CTRL● n=29), b) non-lesional AD skin (NL■ n=32) and c) lesional AD 
skin (L▲ n=14). The red symbols represent the children with FLG loss-of-function mutation(s). Data 
are shown as median ± interquartile ranges. Statistically significant differences; Benjamini-Hochberg  
corrected p-values, between skin types within the groups are indicated with asterisks: **p<0.01. 
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Figure 5 Natural moisturizing factor levels (NMF) in the stratum corneum (SC) within skin type II and 
VI in healthy skin of control children (CTRL ●), non-lesional AD skin (NL ■) and lesional AD skin (L ▲) 
are shown. n=45 in skin type II, n=29 in skin type II without FLG loss-of-function mutation(s) and n=30 
in skin type VI. The red symbols represent the children with FLG loss-of-function mutation(s). Data 
are shown as median ± interquartile ranges. A Mann Whitney U test (MWU-test) was used to 
investigate significant difference between healthy skin versus unaffected AD skin, as the Wilcoxon 
matched-pairs signed rank test (W-test) was used to investigate differences between the paired 
samples of unaffected versus affected AD skin. Statistically significant differences; Benjamini-
Hochberg  corrected p-values are between skin types within the groups are indicated with asterisks: 
*p<0.05; **p<0.01. 
 
Figure 6 Representative AFM images (20 µm) of the surfaces of corneocytes sampled from lesional 
(a) and non-lesional (b) skin of children with AD and c) healthy skin of control children  On visual 
inspection, the number of nano-size protrusions was the highest in AD lesional skin (a). 
 
Figure 7 The Dermal Texture Index (DTI) in the stratum corneum (SC) in healthy skin of control 
children (CTRL●, n=16), in non-lesional AD skin (NL■, n=21) and in lesional AD skin (L▲, n=13). The 
red symbol represents the children with FLG mutation(s). Data are given as median ± interquartile 
ranges. The difference between healthy subgroup and AD subgroups was tested by Mann Whitney U 
test. Wilcoxon Signed Rank test was used to investigate differences between the paired samples of 
non-lesional versus lesional AD skin. Statistically significant difference; Benjamini-Hochberg  
corrected p-values are indicated with asterisks: **p<0.01, **** p<0.0001). 
 
Figure 8 The Dermal Texture Index (DTI)  in the stratum corneum (SC) within skin type II and VI in 
healthy skin of control children (CTRL ●), non-lesional AD skin (NL ■) and lesional AD skin (L ▲) are 
shown. a) skin type II (n=23); b) skin type VI (n=23).  The red symbols represent the children with 
FLG loss-of-function mutation(s). Data are given as median ± interquartile ranges. The difference 
between healthy subgroup and AD subgroups was tested by Mann Whitney U test. Wilcoxon Signed 
Rank test was used to investigate differences between the paired samples of non-lesional versus  
lesional AD skin. Statistically significant difference; Benjamini-Hochberg  corrected p-values are  
indicated with asterisks: *p< 0.05, **p<0.01).  
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Table 1 Patient characteristics  
 
Characteristic Healthy skin 
controls  
(n = 50) 
AD Children 
(n = 53) 
P-values 
Male, n (%) 30 (60.0) 25 (47.2)  
Age (months) 
    mean (± SD) 
    range  
 
75.9 (41.9) 
13-179 
 
41.9 (40) 
5-140 
 
0.02 
Skin type, n (%) 
    I 
 
3 (6.4) 
 
3 (5.7) 
 
    II 20 (36.2) 17 (32.1)  
    III 
    IV 
    V 
    VI 
3 (6.4) 
13 (27.7) 
2 (4.3) 
9 (19.1) 
5 (9.4) 
10 (18.9) 
3 (5.7) 
15 (28.3) 
 
 
 
Objective SCORAD score (mean ± 
SD) 
0 (0) 17.6 (9.7) <0.0001 
FLG carriers, n (%) 
    In skin type  I 
    In skin type II 
    In skintype III 
    In skintype IV 
    In skintype V 
    In skintype VI 
3 (6) 
0 
3 (6) 
0 
0 
0 
0 
14 (27) 
1 (2) 
9 (17) 
2 (4) 
1 (2) 
0 
1 (2) 
0.005 
Season of tape stripping visit (n, 
%) 
  0.004 
    Spring  
    Summer 
    Autumn 
    Winter 
 5 (10) 
38 (76) 
4 (8) 
3 (6) 
17 (32) 
26 (49) 
1 (2) 
 9 (17) 
 
 
AD: atopic dermatitis, Age and objective SCORAD score are expressed as mean with standard deviation, skin type and male 
ratio are expressed as frequency: n is the number of children in each group; with proportion in %, A Mann Whitney U test 
or the chi-square test for was used to investigate significant difference between the two groups: p<0.05.  
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Table 2 Overall association of immunomodulatory mediators with AD severity  
Immunomodulatory 
mediator 
  
Non-lesional AD 
skin 
n=53 
 Lesional 
AD skin   
n=24 
 
 
Spearman r 
 
BH corrected 
p- value 
Spearman r 
 
 
BH corrected 
p- value 
 
IL1 cytokines      
IL1α -0.194 0.299 -0.455 0.089 
IL1β 0.082 0.715 -0.365 0.181 
IL18 0.121 0.569 0.437 0.104 
Inflammatory 
mediators 
    
CXCL8  0.391 0.024 0.533 0.041 
Th2 cytokines     
IL13 0.124 0.558 0.047 0.881 
IL4 -0.005 0.998 -0.388 0.145 
Chemokines     
CCL2 0.291 0.104 0.522 0.044 
CCL13 0.176 0.352 -0.322 0.250 
CCL22 0.272 0.133 0.311 0.267 
CCL17 0.417 0.014 0.504 0.053 
CCL4 0.241 0.183 0.149 0.658 
CXCL10 0.141 0.490 0.398 0.142 
CCL11 0.063 0.776 -0.434 0.104  
     
    Correlation is considered significant if Benjamini-Hochberg  corrected p-values < 0.05 (2-tailed)  
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